Policlinico Le Scotte

At Policlinico Le Scotte in Siena, the cardiovascular research program focuses on chronic heart failure with reduced ejection fraction, with trials designed to assess whether new treatment approaches can better lower the risk of heart-related hospitalizations and cardiovascular death.

• Improving treatment effectiveness in heart failure
• Evaluating a therapy aimed at reducing major cardiovascular events
• Studying outcomes that matter most to patients with advanced heart disease

This area reflects a strong interest in practical, outcome-driven research for people living with serious cardiovascular disease.

The site is also active in oncology, with clinical trials spanning several solid tumors such as melanoma, lung cancer, and other advanced cancers. These studies are mainly aimed at testing new therapies, comparing them with established treatments, and understanding which patients may benefit most.

• Research in advanced solid tumors
• Studies in melanoma and other cancer types
• Evaluating treatment response and long-term benefit

There is also work on ongoing access and continued treatment for people already benefiting from pemigatinib, highlighting the site’s role in supporting patients with complex malignancies.

Research in skin and connective tissue diseases includes studies on chronic spontaneous urticaria and melanoma, showing a mix of inflammatory and cancer-related dermatologic research. The trials are designed to improve symptom control, assess treatment effectiveness, and support better disease management.

• Clinical research in chronic spontaneous urticaria
• Investigations involving melanoma
• Assessing relief of symptoms and overall disease control

These studies add a valuable dermatology-focused dimension to the clinical trial portfolio at Policlinico Le Scotte.